Tags : Development Program


Revance and Mylan to Advance Development Program for a Proposed

Shots: The two companies will advance the development program of a proposed biosimilar to BOTOX and BOTOX Cosmetic (onabotulinumtoxinA), under 351(k) pathways. The US FDA’s feedback during BIAM indicated that the 351(k) regulatory pathways for an onabotulinumtoxinA product is viable Following the advancement of the program, Revance will receive $30M as milestones and is eligible […]Read More